Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

N/AActive Not RecruitingNCT06685848

Hemanext24 enrolled

Overview

The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021 and marketing authorization through the FDA De Novo process in September 2023.

The primary objective is to evaluate whether the total number of hypoxically stored red blood cell (RBCs) units per unit of time transfused in patients with haematologic malignancies, requiring chronic blood transfusion therapy, is non-inferior to the total number of units of conventionally stored RBCs per unit of time transfused. Secondary objectives include the following: 1. Analysis of volume of blood transfused 2. Analysis of number of transfusion events throughout the study period 3. Key laboratory assessments (hemoglobin and hematocrit) and average hemoglobin increment after transfusions of hypoxically stored RBCs compared to that with conventionally stored RBCs 4. Evaluation of Quality of Life (QoL) 5. Change in serum ferritin 6. Safety assessment

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Hematologic Neoplasms

Interventions

Hemanext ONE systemDEVICE

Hypoxic red blood cells

Conventional RBCsDEVICE

Conventional manufactured Red blood cells

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female aged 18 or older * Patients with a documented diagnosis of a haematological malignancy requiring chronic transfusions. * If MDS patient, Have low risk or intermediate risk MDS per either IPSS-R (https://www.mds-foundation.org/ipss-r-calculator/) or IPSS-M (IPSS-M Risk Calculator (mds-risk-model.com)) * If MDS patient, a bone marrow aspirate completed within the 6 months prior to study enrolment, and which did not show progression to higher risk MDS * Have RBC transfusion dependence (at least 2 RBC units /8 weeks during the last 16 weeks) * Baseline RBC transfusion threshold of ≤ 9 g/dL * ECOG (Eastern Cooperative Oncology Group) performance status \< 3 * Have signed the informed consent form and are willing to comply with the study visits and procedures * If on Iron Chelation Therapy, have been on a stable dose for ≥3 months prior to screening Exclusion Criteria: * Have a life expectancy of less than 1 year * Have palpable splenomegaly (more than 3 cm below the mid clavicular line) * Have other associated causes of anemia (including auto-immune hemolysis or active hemorrhage, or progression to acute leukemia) * If prescribed erythropoiesis affecting disease modifying agents (e.g. G-CSF, erythropoietin), have not been on a stable dose for 90 days * Is currently taking Luspatercept or other investigational erythropoiesis affecting disease modifying agent * Have severe renal insufficiency with creatinine clearance (MDRD or CKD EPI) below 30ml/min * Have lung disease with hypoxia or oxygen-dependent * Have severe coronary artery disease (including unstable angina or recent myocardial infraction) or severe heart failure (left ventricular ejection fraction less than 30%) * Have a history of cancer active in the previous 3 years, except local cervix cancer, or basal cell cutaneous carcinoma * Have a history of allo-immunization other than rhesus Kell that cannot be managed by the local blood bank * Are a female of child-bearing potential that is pregnant, planning to become pregnant in the next 14 months or breastfeeding * Are a patient under guardianship or curatorship * Are currently participating in another interventional study evaluating an erythropoiesis affecting disease modifying agent

Locations (2)

Duke University Health System

Durham, North Carolina, United States

Haukeland University Hospital

Bergen, Norway

Outcomes

Primary Outcomes

Number of RBCs units per unit of time

The difference in the total number of hypoxic RBCs units per unit of time transfused to MDS patients during the study period compared to the total number of conventional RBCs units per unit of time transfused.

Time frame: Through study completion, an average of 15 months

Secondary Outcomes

Volume of blood transfused

The mean volume of blood per patient transfused with Hemanext ONE and with standard RBC units will be analyzed and compared

Time frame: Through study completion, an average of 15 months

Number of transfusion events

Mean number of transfusion events throughout the study period

Time frame: Through study completion, an average of 15 months

Mean change in key laboratory assessments (hemoglobin)

Mean change in key laboratory assessments (hemoglobin) and average hemoglobin increment after transfusions of hypoxically stored RBCs compared to that with conventionally stored RBCs.

Time frame: Up to 15-60 minutes post transfusion, up to day 7, up to pre-transfusion of first washout visit (at 6 months), up to transfusion on the final transfusion visit (at 15 months)

Mean change in key laboratory assessments (hematocrit)

Mean change in key laboratory assessments (hematocrit) after transfusions of hypoxically stored RBCs compared to that with conventionally stored RBCs.

Time frame: Up to 15-60 minutes post transfusion, up to day 7, up to pre-transfusion of first washout visit (at 6 months), up to transfusion on the final transfusion visit (at 15 months)

Mean change in QoL

Mean change in QoL as assessed by the EORTC QLQ-C30 (EORTC Quality of Life Questionnaire). Scores from 1-4 (where 1 indicates a better outcome and 4 indicates a worse outcome): 1. Not at all 2. A little 3. Quite a bit 4. Very Much Additionally, a rating from 1-7, where 1 is "Very poor" and 7 is "Excellent"

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.